Overview

A Pilot Study of 68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU or HDR Therapy

Status:
Recruiting

Trial end date:
2022-10-01

Target enrollment:

Participant gender:

Summary

This study is being conducted to determine whether the combination of imaging agents 68-Ga RM2 and 68-Ga PMSA11 is better at assessing response to high intensity focused ultrasound (HIFU) or high dose rate (HDR) local therapy than standard imaging or biopsy in patients with known prostate cancer.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Andrei Iagaru
Stanford University

Collaborator:

General Electric

Treatments:

Bombesin
Edetic Acid
Gallium 68 PSMA-11
Piperidine